index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

89

 

NOTICES

152

 

 

MOTS CLES

Apre-milast Ankylosing spondylitis Biologic Acute Myeloid Leukaemia AML Intensive care Sacroiliitis Adolescent Epidemiology Biological Therapy Antimicrobial resistance Adalimumab Primary adrenal insufficiency Adverse side effects Sipuleucel-T Biologic therapy Cardiotoxicity Spondyloarthritis Anticancer drugs Psoriasis BTK protein Méta-Analyse Management Apremilast Atrial fibrillation Cancer Auto-Diagnostic ASDAS Meta-Analysis Immune-related adverse events Prostate cancer Access to care Burden Stability Addiction Psoriatic arthritis Quality of life Etanercept Aging Axial spondyloarthritis Cardio-oncology Anti-HCV Direct Acting Antivirals DAA Albinism Atopic dermatitis Systematic review Alcohol Pharmaco-Épidémiologie Angiotensin receptor blockers Infliximab Antimicrobial Stewardship Pregnancy Placebo Cardiomyopathy COVID-19 Bacterial rhinosinusitis Vigibase® Biological therapy Dermatology Azathioprine Arthritis Biomédicaments Endocrine toxicity Antimicrobials Biomarkers Pharmacovigilance Ankylosing Bacterial Ustekinumab Drug reaction Amyloidosis Spondylitis ArtThese Biologic drug Treatment Network meta-analysis Ethics Antibiotic misuse Arrhythmia Graft-versus-host disease Drug survival Biosimilar Pharmaceuticals Antibiotic resistance Accelerometer Beta-lactam antibiotics Immunotherapy Autoimmune diseases Anxiety Anxiété Anti-Bacterial Agents Alitretinoin Biologics Pharmacoepidemiology Anti-TNF Angiotensin-converting enzyme inhibitors Glucocorticoids Immune checkpoint inhibitors Antimicrobiens Autoimmunity Auto-immune hepatitis Antibiotics Abus d'antibiotiques

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS